E-ISSN: 1305-3612
MRI-guided biopsy of the prostate: correlation between the cancer detection rate and the number of previous negative TRUS biopsies
PDF
Cite
Share
Request
Interventional Radiology - Original Article
VOLUME: 19 ISSUE: 5
P: 411-417
September 2013

MRI-guided biopsy of the prostate: correlation between the cancer detection rate and the number of previous negative TRUS biopsies

Diagn Interv Radiol 2013;19(5):411-417
DOI: 10.5152/dir.2013.13055
Tahir Durmuş, 1
Uta Reichelt, 2
Alexander Huppertz, 3
Bernd Hamm, 1
Dirk Beyersdorff, 1
Tobias Franiel 4
1. Institute of Radiology, Charite Universitaetsmedizin, Berlin, Germany
2. Department of Pathology, Charite Universitaetsmedizin, Berlin, Germany
3. the Imaging Sciences Institute, Berlin’s Charite Hospital, Berlin, Germany
4. Radiology Center, University Hospital Jena, Jena, Germany
No information available.
No information available
Received Date: 05.02.2013
Accepted Date: 24.03.2013
PDF
Cite
Share
Request

ABSTRACT

PURPOSE

We aimed to investigate prostate cancer detection rate of magnetic resonance imaging (MRI)-guided biopsy and to elucidate possible relations to the number of prior negative transrectal ultrasonography (TRUS)-guided biopsies.

MATERIALS AND METHODS

Eighty-seven consecutive patients (mean age, 65.0 years; mean prostate-specific antigen, 13.3 ng/mL) with at least one prior negative TRUS-guided biopsy and persistent suspicion of prostate cancer were included in this study. All patients underwent MRI-guided biopsy after a diagnostic multiparametric MRI examination at 1.5 Tesla. Specimens were immediately fixated and subsequently evaluated by an experienced uropathologist. Prostate cancer detection rates were calculated. Prostate cancer-positive and -negative cores were compared. Correlation between number of prior biopsies and presence of prostate cancer was evaluated.

RESULTS

Cancer detection rates for patients with one (n=24), two (n=25), three (n=18), and four or more (n=20) negative TRUS-guided biopsies were 29.2%, 40.0%, 66.7%, and 35.0%, respectively (P = 0.087). The median number of removed cores per patient was 3 (range, 1–8) without a significant difference between patients with and without cancer (P = 0.48). 
Thirty of 36 cancer patients were at intermediate or high risk according to the D´Amico clinical risk score. Eleven of 15 high risk cancers were localized in the transition zone (P = 0.002).

CONCLUSIONS

This study demonstrates high cancer detection rates of MRI-guided biopsy independent of the number of previous TRUS-guided biopsies and the number of taken prostate cores. MRI-guided biopsy therefore represents a less invasive and effective diagnostic tool for patients with prostate cancer suspicion and previous negative TRUS-guided biopsies.